NR3C2 and heart failure: Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has been shown to reduce hospitalisations and cardiovascular mortality in patients with HFpEF or heart failure with mildly reduced ejection fraction (EF 40–50%) [92].